📌 Key Takeaways
- Topic: What Is Silica? A Simple Explanation of Silica, Its Forms and Uses
- Keywords: bulk silica powder
- Published: 2026-11-20 10:25:42
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Is Silicon Dioxide Safe? What Science and Regulators Say
- Silica Market Size 2026: Global Value, Growth Rate and Key Segments
- Silica as a Toothpaste Abrasive: How It Cleans and How RDA Is Controlled
- In the case of melt granulation, it is necessary to use meltable excipients that can melt at low temperatures (50-90 °C) as a binder [ 98, 108 ]. The molten binder forms the agglomerates during cooling and solidification. Since it does not need a liquid binder, it is advantageous for use in the case of moisture-sensitive molecules. However, its use should be avoided for heat-sensitive materials.
- Silica Surface Area Explained: Typical BET Values by Type and Why It Matters
- Silica Tapped Density: Definition, Measurement and Typical Values
- Mesoporous Silica Nanoparticles as Drug Delivery Systems
Spherical Silica Manufacturer: Key Capabilities, Purity Control and Selection Criteria
What is silica (SiO₂)?
silica refractive index
What is the difference between fumed silica and precipitated silica?
Aerosil alternative Experiments carried out to investigate the effect of physicochemical properties.
What drives silica raw material prices?
silica pH value Targeted therapy, aiming, for instance, at antitumor treatments, can be divided into active and passive forms [ 72, 73 ]. Passive targeting is based on higher vascularity and higher vascular permeability of the tumor, as well as inflamed tissues, compared to physiological ones [ 73, 74 ]. Additionally, the lymphatic circulation of the tumor shows decreased efficiency [ 25 ], which led to easier accumulation of nanoparticles in the tumor or inflamed tissues [ 10, 27, 72, 74 ]. This passive accumulation is normally called "ELVIS" (Extravasation through Leaky Vasculature and later Inflammatory cell-mediated Sequestration) [ 72, 74 ]. From the facet of surface qualities, negatively charged nanoparticles accumulate less effectively inside cells, due to the negatively charged cell membrane, which slows down the cellular uptake, so, in this case, a neutral surface charge is more favorable [ 25 ]. In contrast, active targeting can be accomplished by functionalizing the outer surface of the silica carriers [ 10, 27, 72 ], where molecules are attached to the surface of the carriers that specifically bind to certain cell surface ligands and receptors, which are characteristic of tumor-, but not of healthy cells. This selective method provides more effective treatment and reduces the side impacts of cytotoxic APIs on healthy cells and tissues [ 10, 27 ]. The most recent findings on active targeting possibilities are summarized in Table 3. García-Fernández et al. prepared a mesoporous silica-based nanocarrier loaded with dexamethasone and capped with a particular protein to actively target the TNFR1 receptor, which is overexpressed in pro-inflammatory macrophages [ 72 ]. Since the carriers are preferably internalized by these macrophages, the cargo is released in a controlled manner, during enzymatic hydrolysis, thus preventing premature drug release, thanks to the gatekeepers. The targeting talent was tested in vitro with activated macrophages. On the other hand, the therapeutic efficiency was tested in vivo in mouse models. The researchers observed greater therapeutic impacts and fewer adverse side influences than in the case of free dexamethasone. To sum up, dexamethasone-loaded MSN has been effectively developed to actively target the lungs in acute lung injury (ALI), and this result may also be promising in other lung diseases (COPD, asthma) [ 72 ]. Teruel et al. presented a novel approach in oral inflammatory bowel sickness (IBD) therapy, using functionalized magnetic mesoporous silica microparticles [ 75 ].
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.